EKF Diagnostics, the Point of Care (PoC) diagnostics company, held a meeting in London to update analysts on business progress and the recent acquisition of Argutus Medical.
EKF Diagnostics CEO Julian Baines and FD Paul Foulger reported that the business is progressing well, having completed three acquisitions in roughly six months (EKF Diagnostics GmbH, Quotient Diagnostics and Argutus). The German based EKF business is operating profitably, and the team has won significant sales contracts in Peru and Mexico with the company's flagship Hemo-Control system. EKF is currently negotiating new distributor relationships for the promising US market (for which it is already approved and CLIA waived).
EKF completed the acquisition of Quotient Diagnostics in October, and is expanding the marketing of its PoC HbA1c testing system for diabetes (QuoTest). QuoTest is important in EKF's strategy because it is a quick, cheap and fast test - appropriate for use in a clinic or doctor's office and central to the growth strategy. QuoTest is approved for sale in Europe and China (cartridge approval pending), and a lower cost version (QuoLab) will be launched in Q3 2011.
EKF recently acquired Dublin based Argutus Medical for £2.2 million in shares. The primary reason for the acquisition is to gain access to Argutus' acute kidney injury (AKI) biomarkers. The AKI market is worth $ 1 billion + globally and has applications in diabetes and sepsis, as well as post-operative applications in coronary bypass and organ transplantation. EKF plans to develop PoC assays using the Argutus biomarkers - ultimatley developing an AKI diagnostic that works in a matter of minutes rather than the 2-3 days that current tests require. Argutus CEO Cormac Kilty will join EKF as Chief Technical Officer - filling the need for a technical expert at the group management level.
Filed Under: Diagnostics, Medical Equipment, Medical, Medical Supplies, Medical Devices, Bioscience,
Disclaimer:
This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.
EKF Diagnostics Holdings Plc, formerly International Brand Licensing plc, designs, develops, manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company is focused within the In-Vitro Diagnostic devices (IVD) market place. Other services include the servicing and distribution of other Company products under separate distribution agreements. The Company operates in Germany, United Kingdom, Ireland, Poland and Russia. On July 2, 2010, the Company acquired 100% interest of EKF-diagnostic Gmbh. On October 4, 2010, the Company acquired 100% of the share capital of Quotient Diagnostics Limited. On December 2, 2010, the Company acquired 100% of the share capital of Argutus Medical Limited. During 2010, the Company discontinued its licensing business and disposed of its portfolio of sports and lifestyle brands. In March 2012, the Company sold International Brand Licensing AG (IBL AG). more »
